Cardiac device therapy articles from across Nature Portfolio

Metabolic reprogramming toward glycolysis is a hallmark of pathological cardiac hypertrophy, but the regulatory mechanisms remain unclear. Here the authors show that the adipokine, asprosin, drives hypertrophic metabolic remodeling by stabilizing PFKP and activating a YY1–asprosin–PFKP–PDK4–PDH axis.

In this Review, Emmert and colleagues provide an overview of the clinically available metallic and polymeric stents used to treat coronary artery disease and valvular heart disease, and discuss the manufacturing techniques used to fabricate these stents, with a focus on the emerging role of 3D-printing technologies.

Drug-coated balloons (DCBs) are used for the treatment of both coronary and peripheral artery disease. In this Review, Byrne and colleagues describe the device design and mechanism of action of DCBs, the scientific and clinical trial evidence for DCB angioplasty and important procedural considerations for successful DCB use.

Baudry et al. review regional participation in heart failure clinical trials, summarize region-specific and regulatory elements that hinder the participation of underrepresented regions, and propose strategies to overcome these obstacles.

Chen et al. developed a self-powered smart magnetoelastic stent for real-time hemodynamic monitoring and stenosis detection.

Wearable cuffless blood pressure monitors can provide important diagnostic and prognostic insights for cardiovascular care. However, their safe and effective clinical adoption depends on rigorous, multi-framework validation strategies capable of ensuring accuracy, building clinical trust and supporting equitable global implementation.

A smart magnetoelastic stent has now been developed to prevent in-stent restenosis after implantation.

In this Tools of the Trade article, Foster and Tabish describe their development of a perfusion platform that recapitulates fundamental haemodynamic features of the human coronary circulation within a controlled flow and pressure environment.

Physical activity lowers the risk of cardiovascular disease and overall mortality. Research now shows that women may derive greater cardiovascular benefit from exercise than men.

Cardiac resynchronization therapy is used to treat dyssynchronous heart failure. Lead-related complications and anatomical constraints can limit pacing lead placement, but leadless systems are now becoming available. These new systems overcome lead-related issues, offering a new option for patients with complex disease (such as congenital heart disease) by eliminating intravascular hardware.